The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 15,472 | 17,345 | 52,303 | - |
| Payroll and related costs | 22,287 | 17,406 | 52,589 | - |
| Lab supplies and outside services | 2,234 | 3,614 | 10,595 | - |
| Facility costs | 2,370 | 2,605 | 7,329 | - |
| Professional services | 3,819 | 2,907 | 8,341 | - |
| Repairs and maintenance | 2,615 | 2,427 | 6,381 | - |
| Change in fair value of the tempus warrants | - | 0 | 0 | - |
| Depreciation and amortization | 2,311 | 2,264 | 7,523 | - |
| Other segment items | 12,040 | 11,504 | 22,588 | - |
| Interest income | 2,172 | 1,570 | 5,585 | - |
| Net loss | -30,032 | -23,812 | -21,652 | -35,806 |
| Stock-based compensation expense | 2,553 | 2,298 | 2,082 | 5,049 |
| Depreciation and amortization | 2,371 | 2,462 | 2,466 | 5,118 |
| Noncash operating lease cost | 161 | 131 | 405 | 799 |
| Amortization of discount on short-term investments | 1,125 | 845 | 942 | 2,204 |
| Other | -21 | 73 | -34 | 263 |
| Accounts receivable | -3,181 | 1,827 | 4,424 | 1,812 |
| Inventory and other deferred costs | 786 | 1,488 | -780 | -504 |
| Prepaid expenses and other assets | -663 | 949 | 142 | 1,133 |
| Accounts payable | -809 | 1,819 | -990 | 3,721 |
| Other long-term liabilities | - | -1,050 | -50 | -100 |
| Accrued and other current liabilities | -426 | 1,782 | 1,818 | -1,294 |
| Contract liabilities | 2,606 | 106 | -169 | -1,475 |
| Operating lease liabilities | -856 | -800 | -1,020 | -2,000 |
| Net cash used in operating activities | -22,478 | -22,246 | -21,804 | -30,896 |
| Purchases of available-for-sale debt securities | 67,040 | 53,727 | 48,150 | 108,297 |
| Proceeds from maturities of available-for-sale debt securities | 24,100 | 39,425 | 68,500 | 84,185 |
| Purchases of property and equipment | 3,192 | 77 | 1,626 | 2,801 |
| Proceeds from sales of property and equipment | 120 | - | - | - |
| Net cash used in investing activities | -46,012 | -14,379 | 18,724 | -26,913 |
| Proceeds from sales of common stock under atm facility, net of commissions | 20,952 | 109,015 | 0 | 17,782 |
| Payment of costs related to tempus and merck investment agreements | - | 83 | 0 | 106 |
| Proceeds from loans | - | 0 | 0 | 2,587 |
| Repayments of loans and finance leases | 1,278 | 284 | 411 | 1,307 |
| Payments for finance lease buyout | 2,125 | - | - | - |
| Proceeds from issuance of common stock under equity incentive plans | 281 | 2,247 | 94 | 804 |
| Net cash provided by financing activities | 17,830 | 110,895 | -317 | 19,760 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 9 | 2 | -4 | 8 |
| Net change in cash, cash equivalents and restricted cash | -50,651 | 74,272 | -3,401 | -38,041 |
| Cash, cash equivalents and restricted cash, beginning of period | 126,035 | 51,763 | 93,205 | - |
| Cash, cash equivalents and restricted cash, end of period | 75,384 | 126,035 | 51,763 | - |